Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe.
OBJECTIVE
To prospectively assess the antibacterial resistance rate in Helicobacter pylori strains obtained from symptomatic children in Europe.


METHODS
During a 4-year period, 17 paediatric centres from 14 European countries reported prospectively on patients infected with H pylori, for whom antibiotic susceptibility was tested.


RESULTS
A total of 1233 patients were reported from Northern (3%), Western (70%), Eastern (9%) and Southern Europe (18%); 41% originated from outside Europe as indicated by mother's birth-country; 13% were <6 years of age, 43% 6-11 years of age and 44% >11 years of age. Testing was carried out before the first treatment (group A, n = 1037), and after treatment failure (group B, n = 196). Overall resistance to clarithromycin was detected in 24% (mean, A: 20%, B: 42%). The primary clarithromycin resistance rate was higher in boys (odds ratio (OR) 1.58; 1.12 to 2.24, p = 0.01), in children <6 years compared with >12 years (OR 1.82, 1.10 to 3.03, p = 0.020) and in patients living in Southern Europe compared with those living in Northern Europe (OR 2.25; 1.52 to 3.30, p<0.001). Overall resistance rate to metronidazole was 25% (A: 23%, B: 35%) and higher in children born outside Europe (A: adjusted. OR 2.42, 95% CI: 1.61 to 3.66, p<0.001). Resistance to both antibiotics occurred in 6.9% (A: 5.3%, B: 15.3%). Resistance to amoxicillin was exceptional (0.6%). Children with peptic ulcer disease (80/1180, 6.8%) were older than patients without ulcer (p = 0.001).


CONCLUSIONS
The primary resistance rate of H pylori strains obtained from unselected children in Europe is high. The use of antibiotics for other indications seems to be the major risk factor for development of primary resistance.
Koletzko
S
S
Dr v Haunersches Kinderspital, Ludwig Maximilians University, Lindwurmstrasse 4, D-80337 Munich, Germany. Sibylle.Koletzko@med.uni-muenchen.de
Richy
F
F
Bontems
P
P
Crone
J
J
Kalach
N
N
Monteiro
M L
ML
Gottrand
F
F
Celinska-Cedro
D
D
Roma-Giannikou
E
E
Orderda
G
G
Kolacek
S
S
Urruzuno
P
P
Martínez-Gómez
M J
MJ
Casswall
T
T
Ashorn
M
M
Bodanszky
H
H
Mégraud
F
F
D000293:Adolescent; D017677:Age Distribution; D000658:Amoxicillin / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D017291:Clarithromycin / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D024901:Drug Resistance, Multiple, Bacterial; D005060:Europe / Q000453:epidemiology; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000150:complications; D011446:Prospective Studies; D017678:Sex Distribution; D017211:Treatment Failure
D000890:Anti-Infective Agents; D008795:Metronidazole; D000658:Amoxicillin; D017291:Clarithromycin